Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 9/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.59 |
| ▸ | GABRP | O00591 | 6/20 | 0.59 |
| ▸ | GABRD | O14764 | 6/20 | 0.59 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.59 |
| ▸ | GABRA4 | P48169 | 6/20 | 0.59 |
| ▸ | GABRE | P78334 | 6/20 | 0.59 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.59 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.59 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.59 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.59 |
| ▸ | TOP2A | P11388 | 2/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388457 | 1.00 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Iodide SCHEMBL9958847 | 0.98 | GABRA1 (0.57) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3233124 | 0.84 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL27074281 | 0.84 | ACHE (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1198673 | 0.82 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9950603 | 0.82 | GABRP (0.52) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30214465 | 0.81 | TOP2A (0.55) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10500769 | 0.81 | TOP2A (0.55) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12240630 | 0.81 | GABRA1 (0.69) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL27014545 | 0.80 | TOP2A (0.43) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865953-A | Preparation method of 7H-indole [2,3-c ] quinoline derivatives based on phosphorescent moieties and having photoresponse | 北京化工大学 | 2024-04-12 | — | — | CN | claimed |
| WO-2010015585-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO[2,3-C]QUINOLINE COMPOUNDS | NYCOMED GMBH (DE) | 2010-02-11 | — | — | WO | claimed |
| US-12558427-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250205342-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-26 | — | — | US | disclosed |
| EP-4499068-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-8288410-B2 | 3-substituted quinolinium and 7H-indolo[2,3-c]quinolinium salts as new antiinfectives | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288410-B2 | 3-substituted quinolinium and 7H-indolo[2,3-c]quinolinium salts as new antiinfectives | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120165369-A1 | 3-SUBSTITUTED QUINOLINIUM AND 7H-INDOLO[2,3-c]QUINOLINIUM SALTS AS NEW ANTIINFECTIVES | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY | 2012-06-28 | — | — | US | disclosed |
| US-20120165369-A1 | 3-SUBSTITUTED QUINOLINIUM AND 7H-INDOLO[2,3-c]QUINOLINIUM SALTS AS NEW ANTIINFECTIVES | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY | 2012-06-28 | — | — | US | disclosed |
| US-20120165369-A1 | 3-SUBSTITUTED QUINOLINIUM AND 7H-INDOLO[2,3-c]QUINOLINIUM SALTS AS NEW ANTIINFECTIVES | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY | 2012-06-28 | — | — | US | disclosed |
| WO-2010015586-A2 | 2,3,4,7-TETRAHYDRO-INDOLO[2,3-C]QUINOLINE COMPOUNDS | NYCOMED GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015585-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO[2,3-C]QUINOLINE COMPOUNDS | NYCOMED GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
| US-4014883-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-03-29 | — | — | US | disclosed |
| US-4014883-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GABRA1 2928/4885GABRG2 3152/4885GABRB3 3487/4885 |
| US-20250205342-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GABRA1 2928/4885GABRG2 3152/4885GABRB3 3487/4885 |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GABRA1 2928/4885GABRG2 3152/4885GABRB3 3487/4885 |
| US-12558427-B2 | IRAK degraders and uses thereof | IRAK1, IRAK2, IRAK3 | GABRA1 1437/4885GABRG2 2417/4885GABRB3 2216/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GABRA1 2928/4885GABRG2 3152/4885GABRB3 3487/4885 |
| US-20120165369-A1 | 3-SUBSTITUTED QUINOLINIUM AND 7H-INDOLO[2,3-c]QUINOLINIUM SALTS AS NEW ANTIINFECTIVES | IDO1, IDO2, NQO2 | GABRA1 2154/4885GABRG2 2806/4885GABRB3 1145/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GABRA1 2928/4885GABRG2 3152/4885GABRB3 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.